These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 4589494)

  • 1. Measurement of therapeutic agents in blood.
    Marks V; Lindup WE; Baylis EM
    Adv Clin Chem; 1973; 16():47-109. PubMed ID: 4589494
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacodynamic and pharmacokinetic measurements in cardiovascular-renal drugs.
    Hayes AH
    Clin Pharmacol Ther; 1974 Jul; 16(1):201-11. PubMed ID: 4843316
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of active drug metabolites on plasma level-response correlations.
    Atkinson AJ; Strong JM
    J Pharmacokinet Biopharm; 1977 Apr; 5(2):95-109. PubMed ID: 323459
    [No Abstract]   [Full Text] [Related]  

  • 4. [Determination of drug concentrations in body fluid; possibilities and limitations. II. Determination of plasma levels as a part of individual patient treatment].
    Ariëns EJ; Simonis AM
    Ned Tijdschr Geneeskd; 1980 Jul; 124(29):1201-12. PubMed ID: 6106163
    [No Abstract]   [Full Text] [Related]  

  • 5. GLC determination of plasma concentration of phenylbutazone and its metabolite oxyphenbutazone.
    Midha KK; McGilveray IJ; Charette C
    J Pharm Sci; 1974 Aug; 63(8):1234-9. PubMed ID: 4852201
    [No Abstract]   [Full Text] [Related]  

  • 6. Simultaneous determination of phenylbutazone and oxyphenbutazone in plasma by high-speed liquid chromatography.
    Pound NJ; Sears RW
    J Pharm Sci; 1975 Feb; 64(2):284-7. PubMed ID: 1127584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When should plasma drug levels be monitored?
    Richens A; Warrington S
    Drugs; 1979 Jun; 17(6):488-500. PubMed ID: 467278
    [No Abstract]   [Full Text] [Related]  

  • 8. [Editorial: To measure or not to measure--that is the question. Problems of measuring blood levels of drugs].
    Preisig R; Bircher J
    Schweiz Med Wochenschr; 1975 Jul; 105(30):933-5. PubMed ID: 1153991
    [No Abstract]   [Full Text] [Related]  

  • 9. Elementary pharmacokinetics in clinical practice. 6: Drug concentration monitoring.
    Paxton JW
    N Z Med J; 1982 Mar; 95(703):150-3. PubMed ID: 6952127
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma drug concentrations in therapeutics.
    Hooper WD; Tyrer JH; Eadie MJ
    Med J Aust; 1976 Mar; 1(10):313-9. PubMed ID: 1272103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assay of phenylbutazone in human plasma by a specific and sensitive gas-liquid chromatographic procedure.
    McGilveray IJ; Midha KK; Brien R; Wilson L
    J Chromatogr; 1974 Feb; 89(1):17-22. PubMed ID: 4815964
    [No Abstract]   [Full Text] [Related]  

  • 12. Simultaneous determination of phenylbutazone and its metabolites in plasma and urine by high-performance liquid chromatography.
    Marunaka T; Shibata T; Minami Y; Umeno Y
    J Chromatogr; 1980 Sep; 183(3):331-8. PubMed ID: 7419650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gas-liquid chromatography in pharmacology and toxicology. Pharmacokinetic analysis limited by the sensitivity of the analytical technique.
    Vree TB; van Rossum JM; Breimer DD; van Ginneken GA; van Kordelaar JM
    Clin Chim Acta; 1971 Sep; 34(2):311-9. PubMed ID: 5113568
    [No Abstract]   [Full Text] [Related]  

  • 14. Binding of drugs by albumin and plasma protein.
    Vallner JJ
    J Pharm Sci; 1977 Apr; 66(4):447-65. PubMed ID: 323460
    [No Abstract]   [Full Text] [Related]  

  • 15. GLC determination of gamma-hydroxyphenylbutazone in plasma.
    Midha KK; McGilveray IJ; Charette C
    J Pharm Sci; 1974 Nov; 63(11):1751-4. PubMed ID: 4427237
    [No Abstract]   [Full Text] [Related]  

  • 16. Oxyphenbutazone and phenylbutazone determination in plasma and urine by GLC.
    Bruce RB; Maynard WR; Dunning LK
    J Pharm Sci; 1974 Mar; 63(3):446-8. PubMed ID: 4820382
    [No Abstract]   [Full Text] [Related]  

  • 17. Chiral pharmacology and its consequences for therapeutic monitoring.
    Hubbard JW; Ganes D; Lim HK; Midha KK
    Clin Biochem; 1986 Apr; 19(2):107-12. PubMed ID: 3518987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interest in the determination of drugs and their metabolites in clinical pharmacology and therapeutics].
    Olive G
    Ann Biol Clin (Paris); 1975; 33(3):171-4. PubMed ID: 1200436
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical use of blood levels of cardiac drugs.
    Atkinson AJ
    Mod Concepts Cardiovasc Dis; 1973 Jan; 42(1):1-4. PubMed ID: 4682595
    [No Abstract]   [Full Text] [Related]  

  • 20. A supercritical fluid chromatographic method using packed columns for phenylbutazone and oxyphenbutazone in serum, and for phenylbutazone in a dosage form.
    Simmons BR; Jagota NK; Stewart JT
    J Pharm Biomed Anal; 1995 Jan; 13(1):59-64. PubMed ID: 7718635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.